Imugene Limited (ASX:IMU)
Australia · Delayed Price · Currency is AUD 0.0370
+0.0010 (2.78%)
Oct 21, 2026, 4:10 PM AEDT
Imugene Revenue
In the fiscal year ending June 30, 2026, Imugene had annual revenue of 2.09M AUD, down -53.07%. Imugene had revenue of 1.28M in the half year ending June 30, 2026. That makes Imugene the 42,986th largest company in the world by revenue and 910th in Australia.
Revenue
2.09M
Revenue Growth
-53.07%
P/S Ratio
8.69
Revenue / Employee
149.01K
Employees
14
Market Cap
18.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.09M | -2.36M | -53.07% |
| Jun 30, 2025 | 4.45M | -524.62K | -10.56% |
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 12.87M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| ReNerve | 510.36K |
| NeuroScientific Biopharmaceuticals | 402.66K |
Imugene News
- 7 weeks ago - Imugene Annual report: H2 2026 - Filings
- 4 months ago - Imugene Slides: Study update presentation - Filings
- 5 months ago - Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU) - GlobeNewsWire
- 5 months ago - Imugene Earnings release: Q3 2026 - Filings
- 7 months ago - Imugene Quarterly report: H1 2026 - Filings
- 8 months ago - Imugene Earnings release: Q2 2026 - Filings
- 10 months ago - Imugene Transcript: FDA Meeting Update - Transcripts
- 10 months ago - Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours - PRNewsWire